WT1 and acute myeloid leukemia: In a phase I/II trial, Tendeloo et al. assessed the DC-WT1 vaccine in 10 AML patients who achieved CR or PR following chemotherapy and were at a high risk of relapse (Van Tendeloo et al., 2010).